Understand the source comparison
Peptide Clinics North Carolina Providers Services 2026: Comparison
Before selecting a peptide provider in North Carolina for 2026 research projects, compare regulatory classification, purity documentation, and supply chain integrity across provider types. 503B Compounding Pharmacy FDA-registered outsourcing facility; sterile
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide provider in North Carolina for 2026 research projects, compare regulatory classification, purity documentation, and supply chain integrity across provider types.
- 503B Compounding Pharmacy
- FDA-registered outsourcing facility; sterile compounding under cGMP
- USP <797> compliance; sterility testing; no individual batch HPLC for research distribution
- Patient-specific peptide formulations under prescription
- Yes. Temperature-controlled shipping with monitoring
- Not accessible for research use; peptides classified as drug products restricted to prescription channels
- Research-Grade Peptide Supplier
- Laboratory reagent distributor; 'Not for Human Consumption' labeling
- Third-party HPLC ≥98% purity; CoA per batch; mass spectrometry confirmation
- In vitro studies, animal models, mechanistic research
- Yes. Lyophilised peptides shipped at 2–8°C with documentation
- Standard for institutional research; meets IRB and grant compliance requirements
- Wellness/Anti-Aging Clinic
- Variable; some operate under physician oversight, others in regulatory grey zones
- Often unavailable or undocumented; no third-party verification
- Off-label therapeutic use; not research
- Inconsistent; no standardised cold-chain protocols
- Avoid for research. No traceable sourcing, compliance risk, no institutional acceptance
- This table clarifies that peptide clinics North Carolina providers services 2026 are not interchangeable. Institutional researchers require Category 2 suppliers with documented synthesis and third-party testing. Clinical researchers working under IRB protocols with human subjects require Category 1 (503B) peptides prescribed through licensed physicians. Wellness clinics (Category 3) serve neither use case reliably.